Coastar Therapeutics announced today that the company will participate in the upcoming BIOCOM 2026 Conference hosted by Biocom California, February 24-26. Coastar’s Founder and CEO, Eddie Chung, will deliver a company presentation highlighting recent progress and strategic milestones.

The BIOCOM Conference brings together leaders across biotechnology, pharmaceutical development, venture capital, and academic research to discuss innovation shaping the future of life sciences in California and beyond. Coastar’s participation underscores its growing role in advancing next-generation gene delivery technologies that enables more effective and accessible genetic medicine. 

“BIOCOM provides an important forum to engage with partners, investors, and industry peers,” said Mr. Chung. “We look forward to sharing our recent progress and outlining how Coastar’s platform is positioned to enable safer, scalable in vivo gene delivery.”

Attendees interested in learning more are encouraged to connect with the Coastar team during the conference. 

About Coastar Therapeutics

Coastar Therapeutics Inc., is a San Diego based company developing biological payload delivery technologies for cancer and gene therapies. The company’s proprietary gene delivery technology enables effective, precision targeted and highly scalable in vivo delivery of genetic medicine, including DNA, RNA as well as viral vectors. The company is working with a number of global partners to develop next generation therapeutic products.  For more information about Coastar Therapeutics and its mission, visit coastartherapeutics.com.

About Biocom 2026

Biocom’s 16th Annual Global Life Science Partnering & Investor Conference is an exclusive global partnering and networking forum that brings together over 500 investors and senior executives, including CEOs and heads of business development, licensing, M&A, and research and development from leading pharmaceutical, biotech, and research organizations from over 20 countries.